NCT Number: NCT04989946
Phase: Phase 1|Phase 2
Trial Summary: The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives